Recurrent and clonal genetic alterations in different subtypes of Acute Lymphoblastic Leukemia (ALL) are well-characterized and known to be strong independent predictors of disease outcome. The conventional SALSA® MLPA® technology is one of the standard methods for the detection of IKZF1 deletions, which are associated with unfavorable outcome in childhood ALL. To increase genomic coverage, the newer SALSA® digitalMLPA™ technology was employed to create a novel, all-encompassing ALL panel: SALSA® digitalMLPA Probemix D007 Acute Lymphoblastic Leukemia.
Rate the quality of this page
Disclaimer
The information provided in this material is correct for the majority of our products. However, for certain applications, the instructions for use may differ. In the event of conflicting information, the relevant instructions for use take precedence.